258 related articles for article (PubMed ID: 28099882)
1. The 35-year odyssey of beta blockers in cirrhosis: any gender difference in sight?
Burza MA; Marschall HU; Napoleone L; Molinaro A
Pharmacol Res; 2017 May; 119():20-26. PubMed ID: 28099882
[TBL] [Abstract][Full Text] [Related]
2. Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis.
Gillespie SL; Hanrahan TP; Rockey DC; Majumdar A; Hayes PC
Aliment Pharmacol Ther; 2023 Mar; 57(5):454-463. PubMed ID: 36691947
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Oesophageal Varices in Liver Cirrhosis.
Sauerbruch T; Wong F
Digestion; 2019; 99(4):261-266. PubMed ID: 30212817
[TBL] [Abstract][Full Text] [Related]
4. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding.
Pfisterer N; Dexheimer C; Fuchs EM; Bucsics T; Schwabl P; Mandorfer M; Gessl I; Sandrieser L; Baumann L; Riedl F; Scheiner B; Pachofszky T; Dolak W; Schrutka-Kölbl C; Ferlitsch A; Schöniger-Hekele M; Peck-Radosavljevic M; Trauner M; Madl C; Reiberger T
Aliment Pharmacol Ther; 2018 Apr; 47(7):966-979. PubMed ID: 29388229
[TBL] [Abstract][Full Text] [Related]
5. Beta-blockers in liver cirrhosis.
Giannelli V; Lattanzi B; Thalheimer U; Merli M
Ann Gastroenterol; 2014; 27(1):20-26. PubMed ID: 24714633
[TBL] [Abstract][Full Text] [Related]
6. Beta-blockers for prophylaxis of bleeding from esophageal varices in cirrhotic portal hypertension. Review of the literature.
Zoller WG; Gross M
Eur J Med Res; 1996 Jun; 1(9):407-16. PubMed ID: 9353240
[TBL] [Abstract][Full Text] [Related]
7. NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: "THE THERAPEUTIC WINDOW".
Dimache M; Gîrleanu I; Carpov E; Trifan A; Stanciu C
Rev Med Chir Soc Med Nat Iasi; 2016; 120(1):23-8. PubMed ID: 27125068
[TBL] [Abstract][Full Text] [Related]
8. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers.
Shukla R; Kramer J; Cao Y; Ying J; Tansel A; Walder A; Advani S; El-Serag HB; Kanwal F
Am J Gastroenterol; 2016 Dec; 111(12):1778-1787. PubMed ID: 27670600
[TBL] [Abstract][Full Text] [Related]
9. Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial.
Patel VC; McPhail MJ; Uddin R; Jafari H; Lawrence V; Le Boutillier C; Shearer J; Yaziji N; Cape A; Ahmed H; Ward C; Walsh P; Besly K; Zamalloa A; Kelly J; ; Carter B
Trials; 2024 Apr; 25(1):265. PubMed ID: 38627804
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices.
Paternostro R; Becker J; Hofer BS; Panagl V; Schiffke H; Simbrunner B; Semmler G; Schwabl P; Scheiner B; Bucsics T; Bauer D; Binter T; Trauner M; Mandorfer M; Reiberger T
Dig Liver Dis; 2022 Apr; 54(4):500-508. PubMed ID: 34799282
[TBL] [Abstract][Full Text] [Related]
11. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study.
Kang SH; Lee M; Kim MY; Lee JH; Jun BG; Kim TS; Choi DH; Suk KT; Kim YD; Cheon GJ; Kim DJ; Baik SK
Hepatol Int; 2021 Apr; 15(2):424-436. PubMed ID: 33860898
[TBL] [Abstract][Full Text] [Related]
12. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.
Turco L; Reiberger T; Vitale G; La Mura V
Liver Int; 2023 Jun; 43(6):1183-1194. PubMed ID: 36897563
[TBL] [Abstract][Full Text] [Related]
13. The portal hypertension syndrome: etiology, classification, relevance, and animal models.
Bosch J; Iwakiri Y
Hepatol Int; 2018 Feb; 12(Suppl 1):1-10. PubMed ID: 29064029
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.
Reiberger T; Ulbrich G; Ferlitsch A; Payer BA; Schwabl P; Pinter M; Heinisch BB; Trauner M; Kramer L; Peck-Radosavljevic M;
Gut; 2013 Nov; 62(11):1634-41. PubMed ID: 23250049
[TBL] [Abstract][Full Text] [Related]
15. Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis.
Kim BH; Chung JW; Lee CS; Jang ES; Jeong SH; Kim N; Kim JW
Korean J Intern Med; 2019 Nov; 34(6):1233-1243. PubMed ID: 30759966
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic prevention of variceal bleeding and rebleeding.
Baiges A; Hernández-Gea V; Bosch J
Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
[TBL] [Abstract][Full Text] [Related]
17. Effect of Nonselective β-Blockers on Mortality in Patients With End-Stage Cirrhosis.
Snoga JL; Lusk KA; Attridge RT; Attridge RL
Ann Pharmacother; 2020 Apr; 54(4):322-330. PubMed ID: 31701773
[No Abstract] [Full Text] [Related]
18. Beta-blockers and cirrhosis: Striking the right balance.
Cromer M; Wilcox CM; Shoreibah M
Am J Med Sci; 2024 Apr; 367(4):228-234. PubMed ID: 38262558
[TBL] [Abstract][Full Text] [Related]
19. Beta-blockers in portal hypertension: new developments and controversies.
Tripathi D; Hayes PC
Liver Int; 2014 May; 34(5):655-67. PubMed ID: 24134058
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic Response to Carvedilol is Maintained for Long Periods and Leads to Better Clinical Outcome in Cirrhosis: A Prospective Study.
Kirnake V; Arora A; Gupta V; Sharma P; Singla V; Bansal N; Goyal M; Chawlani R; Kumar A
J Clin Exp Hepatol; 2016 Sep; 6(3):175-185. PubMed ID: 27746613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
